Telo Genomics Announces that Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within ASH...
13 Octobre 2020 - 3:15PM
Telo Genomics Corp. (TSX-V: TELO)
(the
“Company” or
“TELO”) is
pleased to announce that its abstract submitted to the American
Society of Hematology (ASH) annual meeting 2020, reporting on
positive results achieved from a diagnostic/prognostic smoldering
multiple myeloma (SMM) ‘proof of concept’ study, was selected for
online publication. The abstract will be included in the November
supplemental issue of the scientific
journal
Blood, published by ASH.
The SMM proof of concept study was conducted in
collaboration between TELO Genomics and Dr. Sabine Mai’s research
laboratory. The study was conducted using TELO’s proprietary
TeloView® technology. Dr. Mai is co-Founder, Director and Chair of
the Clinical and Scientific Advisory Board of TELO. The specific
data from the study has been embargoed until the publication of the
journal.
The American Society of Hematology is a
professional organization representing healthcare professionals
involved in the management of blood disorders including blood
cancers. The ASH annual meeting is considered one of the top
clinical international meetings focused on blood cancers and
hematological malignancies. ASH annual meeting attracts more than
30,000 attendees every year, predominantly clinicians from all over
the world.
Smoldering multiple myeloma is a an asymptomatic
precursor to active multiple myeloma (MM), a highly challenging
blood cancer that forms in plasma cells, a type of white blood
cell. There is an increasing industry trend towards trying to
identify high-risk SMM patients to initiate early treatment and
achieve better clinical outcomes (Kapoor & Rajkumar 2019). The
MM annual incidence rate is approximately 32,000 newly diagnosed
cases in the USA per year, with approximately 250,000 cases of SMM,
and 10-15% of SMM patients progress to active MM every year.
“We are excited to publish the positive results
of the SMM ‘proof of concept’ study within the proceedings of ASH
2020 in such a prestigious journal,” said Sherif Louis, TELO’s CEO.
“These results provide added confidence in the outcomes of the
ongoing SMM studies TELO is currently conducting.”
Reference: Smoldering Multiple
Myeloma: To Treat or Not to Treat. Kapoor P, Rajkumar SV.
Cancer J. 2019 Jan/Feb;25(1):65-71.
About Telo
Genomics
Telo Genomics is a biotech company pioneering
the most comprehensive telomere platform in the industry with
powerful applications and prognostic solutions. These include
liquid biopsies and related technologies in oncology and
neurological diseases. Liquid biopsy is a rapidly growing field of
significant interest to the medical community for being less
invasive and more easily replicated than traditional diagnostic
approaches. By combining our team’s considerable expertise in
quantitative analysis of 3D telomeres with molecular biology and
artificial intelligence to recognize disease-associated genetic
instability, Telo Genomics is developing simple and accurate
products that improve day-to-day care for patients by serving the
needs of pathologists, clinicians, academic researchers and drug
developers. The benefits of our proprietary technology have been
substantiated in over 150 peer reviewed publications and in 25
clinical studies involving more than 3,000 patients with multiple
cancers and Alzheimer’s disease. Our lead application, Telo-MM is
being developed to provide important, actionable information to
medical professionals in the treatment of Multiple Myeloma, a
deadly form of blood cancer. For more information please visit
www.telodx.com.
For further information, please
contact:
Hugh
RogersDirector416-673-8487info@telodx.comMaRS Centre, South Tower,
101 College Street, Suite 200, Toronto, ON, M5G
1L7www.telodx.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as such term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
Certain information contained herein may
constitute “forward-looking information” under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as
“intends”, “will”, or variations of such words and phrases or
statements that certain actions, events or results “will” occur.
Forward-looking statements regarding the clinical efficacy of
products, commercial viability of products, use of proceeds, and
the ability of the TeloViewTM platform to deliver personalized
medicine resulting in better treatments and outcomes are based on
the Company’s estimates and are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information,
including capital expenditures and other costs. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward- looking statements and
forward-looking information. The Company will not update any
forward-looking statements or forward-looking information that are
incorporated by reference herein, except as required by applicable
securities laws.
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Telo Genomics (TSXV:TELO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024